Accelerating Success

From start-up to standout.

We provide start-ups with a structured and comprehensive toolkit for development, milestone achievement and eventual autonomy. Take a look at a few of the success stories from our growing portfolio of diverse and exciting companies.

Source:
MD Anderson Cancer Center

Technology:
Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.

Series A:
$31M

Investment Date:
Q3 2018

Web site

Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death.

Technology:
To develop new medical countermeasure for nerve agent exposure

Web site

To develop new medical countermeasure for nerve agent exposure

Source:
Case Western Reserve University, University of Texas Southwestern Medical Center

Technology:
First-in-class therapies for enhancing tissue repair and regeneration

Series A:
$5.9M

Investment Date:
Q3 2017

Web Site

First-in-class therapies for enhancing tissue repair and regeneration

Source:
University of Minnesota

Technology:
Oncology: A new class of therapies to break drug resistance in cancer

Series A:
$7M

Investment Date:
Q4 2016

Web Site

A new class of therapies to break drug resistance in cancer

Source:
The Rockefeller University

Technology:
New generation of natural product derived therapeutics for human disease.

Series A:
$20M

Investment Date:
Q1 2016

Web Site

New generation of natural product derived therapeutics for human disease.

Source:
Weill Cornell Medicine

Technology:
Novel approach to therapeutics for cancer and metabolic diseases.

Series A:
$48M

Investment Date:
Q1 2016

Graduation Date:
Q3 2017

Web site

Novel approach to therapeutics for cancer and metabolic diseases.